ESPR Esperion Therapeutics Inc.

RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500

RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500

NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500

CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) --  RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid). NEXLIZET will be featured on Keselowski’s No. 6 Ford at this year’s Daytona Speedweeks, including the famed Daytona 500 on February 19. NEXLETOL will be featured throughout the season on Chris Buescher’s No. 17 Ford.

Headquartered in Ann Arbor, Michigan, Esperion discovers, develops, and commercializes innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by current treatment options.

“We’re thrilled to have Esperion, a company that is making waves in the pharmaceutical industry, on board with us,” said Steve Newmark, President of RFK Racing. “We look forward to working with Esperion to create engaging content around their two products in NEXLIZET and NEXLETOL and showcasing their debut on the No. 6 for the famed Daytona 500. We’re thankful to the team at Esperion and can’t wait to introduce them to the sport in a big way in 2023.”

In addition to the Daytona 500 (Feb. 19, 2:30 p.m. ET, FOX), Esperion will serve as a primary on the No. 6 Ford at the All-Star Race at North Wilkesboro Speedway (May 21, 8 p.m. ET, FS1) and RFK’s home track at Michigan (Aug. 6, 2:30 p.m. ET, USA).

The brand will serve as a primary on the No. 17 at Las Vegas (March 5, 3:30 p.m. ET, FOX), Martinsville Spring (April 16, 3 p.m. ET, FS1), and Martinsville Fall (Oct. 29, 2 p.m. ET, NBC).

“We’re excited to partner with RFK Racing to increase brand awareness, and this sponsorship provides ample opportunities for community engagement and education to their large and diverse consumer base to advance awareness about the benefits of lowering LDL cholesterol and improving cardiovascular health,” said Sheldon Koenig, Esperion’s President and CEO.

Keselowski enters his second season at RFK and 14th full season in the NASCAR Cup Series (NCS). With 35 Cup wins to his credit, he is set to make his 500th Cup start in 2023. Buescher, now in his fourth season back with RFK, embarks on his eighth full-time season of Cup competition.

At Daytona and Michigan combined, Keselowski has 19 combined top-10 efforts, including a win in the 2022 Duels where RFK swept the season-opening exhibition qualifying races. At the two-mile Michigan facility, he has top-10s in half of his all-time starts in his home state.

Coming off a victory in the historic Bristol Night Race, Buescher will carry the NEXLETOL banner at another short track in Martinsville, in addition to the race at Las Vegas.

The 2023 NASCAR season unofficially kicks off with the Clash at the Coliseum (8 p.m. ET, FOX) on Sunday, Feb. 5, in Los Angeles. Coverage of Daytona 500 week begins on Wednesday, Feb. 15, with full-field qualifying, followed by the Duels on Thursday, and a pair of practice sessions set to take place Friday and Saturday.

About Esperion

Esperion works hard to make our medicines easy to get, easy to take, and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit esperion.com and follow us on Twitter at /EsperionInc. 

About RFK Racing

RFK Racing, in its 36th season in 2023, features an ownership lineup pairing one of the sport’s most iconic names, Jack Roush, along with NASCAR Champion, Brad Keselowski, and Fenway Sports Group owner John Henry. Roush initially founded the team in 1988 and it has since become one of the most successful racing operations in the world, propelling him to be the first NASCAR owner to amass three hundred wins and capturing eight championships, including back-to-back NASCAR Cup titles in 2003 and 2004. Keselowski, a former owner in the NASCAR Truck Series, brings to the team a championship mindset himself having won the 2012 NASCAR Cup Series Championship. In 2007, Roush partnered with Henry, who also owns Major League Baseball’s Boston Red Sox, English Premier League’s Liverpool F.C., and the NHL’s Pittsburgh Penguins, to form Roush Fenway Racing. Off the track, RFK is a leader and proven winner in NASCAR marketing solutions, having produced multiple award-winning social media, digital content and experiential marketing campaigns. Visit , and follow the team on all social platforms @rfkracing.

Contact:

Esperion Corporate Communications





EN
11/01/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE

Esperion to Participate in Upcoming September Investor Conferences

Esperion to Participate in Upcoming September Investor Conferences ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of September, which can be found on our investor relations . Cantor Global Healthcare Conference in New York on September 3, 2025, at 9:45 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 p.m. ET. Live webcasts can be accessed on the investor and media section of the Esperio...

 PRESS RELEASE

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such indivi...

 PRESS RELEASE

Esperion Reports Second Quarter 2025 Financial Results and Provides Bu...

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL® (bempedoic acid) Prior to 2040 – – First Quarter of Operating Income from Ongoing Business with Plans for Sustainable Profitability Starting in Q1 2026 – – Conference Call and Webcast Today at 8:00 a.m...

 PRESS RELEASE

Esperion to Report Second Quarter 2025 Financial Results on August 5

Esperion to Report Second Quarter 2025 Financial Results on August 5 ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after completion of the call and...

 PRESS RELEASE

Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Mar...

Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., July 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Accord Healthcare Inc. This agreement resolves the patent litigation brought by Esperion against Accord Healthcare Inc. in response to Accord Healthcare Inc’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch